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Abstract
Drug-induced liver injury (DILI) is a major concern for patients, care givers and the 
pharmaceutical industry. Interpretation of the serum biomarkers routinely used to detect and 
monitor DILI, which have not changed in almost 50 years, can be improved with recently 
proposed models employing quantitative systems pharmacology. In addition, several newer serum 
biomarkers are showing great promise. Studies in rodents indicate that the ratio of the caspase 
cleaved fragment of cytokeratin 18 to total K18 in serum (termed the “apoptotic index”) estimates 
the relative proportions of apoptosis vs necrosis during drug-induced liver injury. Glutamate 
dehydrogenase can reliably differentiate liver from muscle injury and, when serum is properly 
prepared, may also detect mitochondrial toxicity as a mechanism of liver injury. MicroRNA-122 is 
liver-specific, but recent data suggests it can be actively released from hepatocytes in the absence 
of overt toxicity limiting enthusiasm for it as a DILI biomarker. Finally, damage associated 
molecular patterns, particularly high mobility group box 1 and its various modified forms, are 
promising biomarkers of innate immune activation, which may be useful in distinguishing benign 
elevations in aminotransferases from those that portend clinically important liver injury. These 
new biomarkers are already being measured in early clinical trials, but broad acceptance will 
require widespread archiving of serum from diverse clinical trials and probably pre-competitive 
analysis efforts. We believe that utilization of a panel of traditional and newer biomarkers in 
conjunction with quantitative systems pharmacology modeling approaches will transform DILI 
detection and risk management.
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Drug Induced Liver Injury (DILI)
Drug induced liver injury (DILI) accounts for greater than half of all acute liver failure 
(ALF) cases occurring in the United States.1 The majority of DILI cases that lead to ALF are 
due to overdose of acetaminophen which is considered an “intrinsic” liver toxin. Intrinsic 
hepatotoxicity due to drugs is typified by direct chemical damage to liver cells, a short 
latency period, and a clear dose-dependent response.2 Intrinsic hepatotoxins would cause 
liver injury in virtually all patients if they received sufficient overdoses, although the 
threshold for toxic response can show marked inter-individual differences. Intrinsic 
hepatoxins are generally identified as such in preclinical animal testing and in Phase 1 dose 
escalation clinical trials.
Intrinsic hepatoxins are to be distinguished from idiosyncratic hepatoxins, which cause 
clinically significant DILI in only a very small minority of treated individuals, typically less 
than 1 in 10,000.3 While rare, idiosyncratic DILI (iDILI) events carry a significant risk for 
liver failure. 4, 5 Although there appears to be a dose threshold required to elicit iDILI, 
overdosing generally does not produce liver toxicity in most treated patients.6 There is often 
a prolonged latency between initiation of treatment and the onset of iDILI. iDILI is 
particularly problematic in drug development because preclinical testing and early clinical 
trials generally fail to identify iDILI liabilities, which may only become evident late in 
Phase 3 clinical development or post-marketing use, after thousands of patients have 
received prolonged treatment with the drug.
Traditional DILI Biomarkers and Hy’s Law
For about the last half century, the serum biomarkers routinely utilized to detect and manage 
DILI in clinical trials and in the clinic are alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL). ALT and 
AST are present within hepatocytes and during an acute DILI event, increased serum levels 
of ALT and AST should generally correlate well with the rate at which hepatocytes are 
dying and releasing their contents. Elevation in serum ALP generally indicates injury to the 
canalicular membrane or biliary epithelial cells. Elevated levels of TBIL may reflect hepatic 
functional impairment, or alterations in bilirubin production (hemolysis) or processing. 
However, these traditional serum biomarkers suffer from several shortcomings. None of 
these markers are completely specific to liver injury or provide mechanistic insight into the 
mode of injury. Additionally, release of cellular injury biomarkers such as ALT and AST 
into the circulation takes place when hepatocyte injury has already occurred and therefore 
these biomarkers cannot be utilized to identify a potential for DILI prior to the appearance of 
overt liver injury.7, 8 Moreover, elevations in serum ALT/AST can occur during treatment 
with drugs that do not pose much or any risk of progressive liver injury (eg. statins, tacrine, 
heparins and cholestyramine).9–11 Even when drugs are capable of causing progressive and 
clinically important liver injury, most drug-induced elevations in serum ALT and AST 
resolve despite continued treatment with the offending drug – a process termed 
“adaptation.”12
Church and Watkins Page 2
Liver Int. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Recognizing the limitations of serum ALT and AST in assessing liver safety in clinical trials 
of new drug candidates, a 2009 FDA guidance defined a “Hy’s Law” case as the event that 
most accurately predicts the potential for a drug to cause acute liver failure.13 This is based 
on observations by Dr. Hyman Zimmerman, and confirmed in large international DILI 
registries, that patients with hepatocellular jaundice due to a medication have at least a 10% 
chance of developing liver failure.4, 14, 15 According to the FDA guidance, a Hy’s Law case 
is a patient with a healthy liver at the start of a clinical trial who experiences hepatocellular 
injury characterized by a rise in serum ALT >3X above an established upper limit of normal 
(ULN) and also a rise in serum TBIL >2X ULN with no more likely explanation for the 
event than the study drug. The assumption is that the rise in serum TBIL has resulted from 
global loss of liver function due a substantial loss of viable hepatocytes. It should be noted 
that in a true Hy’s Law case, the combined elevations in serum ALT and TBIL are not 
biomarkers that predict the potential for severe liver injury, but are biomarkers documenting 
that severe and potentially life-threatening liver injury has occurred in this subject.
A challenge to interpreting a Hy’s Law case is that drugs may cause elevations in serum 
TBIL for reasons other than impairment of global liver dysfunction. Reasons include 
hemolysis (increased heme load), inhibition by the drug of the uptake or efflux proteins that 
transport bilirubin, or inhibition of the major hepatocyte enzyme that conjugates bilirubin 
(UGT1A1). Quantitative systems pharmacology has been recently applied to integrate 
estimates of liver exposure to a drug with the quantified effects of the drug on inhibiting the 
transporters and UGT1A1 as assessed in in vitro systems.15 This approach should advance 
understanding and prediction of drug-induced elevations in serum TBIL not due to global 
liver dysfunction.
It has also been recently proposed that the percent of hepatocytes dying in an acute DILI 
event can be assessed from serial measurements of serum ALT.16 This is based on the idea 
that each hepatocyte contains a finite amount of ALT which is passively released during cell 
death. The area under the serum ALT vs. time curve should therefore correspond to the 
number of hepatocytes lost. Furthermore, it has been proposed that the estimate of 
hepatocyte loss obtained in this way can be used to predict the magnitude in rise of serum 
bilirubin expected based on the implied loss of aggregate liver function. Hepatectomy 
studies in animals suggest that over 70% of hepatocytes must be lost before there is a rise in 
serum TBIL sufficient to cause jaundice.17 In an acute DILI event, however, function would 
be expected to be impaired in a proportion of hepatocytes that may not undergo cell death. 
Supportive data to incorporate this phenomenon into the ALT derived estimate of hepatocyte 
loss may be a liver biopsy study conducted several decades ago in patients experiencing liver 
injury due to acetaminophen overdose.18 From data provided by this study, it can be 
concluded that more that 40% of hepatocytes must die before serum TBIL will rise to 
greater than 2X ULN. This estimate has been used together with the AUC of serum ALT in 
two subjects who experienced elevations in serum ALT >3X ULN and serum TBIL >2X 
ULN believed due to study drug, i.e. both were Hy’s Law cases by current definition. The 
serial serum ALT values resulted in estimates predicting the loss of hepatocytes as far less 
than 40% in each subject.19 The conclusion from the modeling was that the rise in serum 
TBIL was not due solely to hepatocellular toxicity. This conclusion would be further 
supported if the systems pharmacology approach indicated that transporter and/or enzyme 
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inhibition by the drug likely contributed to the observed rise in serum TBIL.15 These 
approaches hold the potential to refine interpretation of potential Hy’s Law cases.
Newer DILI biomarkers
The use of serial serum ALT values to assess percent hepatocyte loss assumes that the 
majority of ALT entering circulation is the result of hepatocytes dying with release of their 
content of ALT. This is likely to be the case in serious DILI events, but substantial elevations 
in serum ALT may also result from muscle disease or injury.20, 21 MicroRNA-122 
(miR-122) and glutamate dehydrogenase (GLDH) have been proposed as more sensitive and 
specific biomarkers of liver injury than ALT. The mode of hepatocyte death, apoptosis or 
necrosis, is also likely to influence the calculations of percent hepatocyte loss based on serial 
measurement of ALT (or other intracellular hepatocyte proteins) in serum. This is because in 
apoptosis, hepatocyte proteins and RNA species may be largely degraded prior to release 
into circulation. In this regard, an “apoptotic index” (AI) based on serum biomarkers has 
been recently proposed to estimate the relative contributions of apoptosis and necrosis to 
liver injury. As is the case with serum ALT, optimal interpretation of these newer biomarkers 
will benefit from modeling that incorporates the release and clearance kinetics of each.
The “Apoptotic Index”—The AI is the ratio of caspase cleaved keratin 18 (ccK18) to 
total keratin 18 (K18; comprising both full length K18 and caspase cleaved fragments). K18 
is a type I intermediate filament found in epithelial cells that provides structural support for 
cells. Early during apoptosis, K18 is cleaved by caspases, resulting in a stable fragmented 
form of the protein (ccK18) that is released into circulation (Figure 1).22 During necrosis, 
full-length K18 is released passively into circulation but little ccK18 should be released. 
Mass spectrometry (for mice) or immunoassays (for humans) that detect K18 or ccK18 
concentrations in blood have been investigated in acetaminophen-induced liver injury (AILI) 
to determine whether they correlate with extent of necrosis vs. apoptosis, respectively, 
occurring in the liver.23 In mice, elevated levels of ccK18 correlated strongly with 
procaspase processing, DNA fragmentation, and the appearance of apoptotic hepatocytes 
that expressed caspase 3.24 Additionally, the ratio of ccK18 to K18 mirrored the time-
dependent shift in the liver from mixed apoptosis/necrosis to primarily necrotic injury. It has 
also been noted that, in AILI, there is a significant elevation of both K18 and ccK18 levels 
prior to a significant elevation in ALT levels.24 These data suggest that, at least in preclinical 
models, quantifying K18 and ccK18 may provide both an early detection of hepatocyte cell 
death and a quantitative estimate of the relative amounts of apoptosis vs. necrosis occurring 
in the liver. Since K18 is not limited to epithelial cells of hepatic origin, utilizing it on its 
own as a DILI biomarker may be problematic because it assumes that liver is the only organ 
experiencing cell death. The ratio of miR-122 or GLDH to K18 may permit such a 
conclusion, but this has not yet been investigated.
Quantification of serum K18 and ccK18 has also been conducted in the setting of clinical 
DILI.25–27 Both have demonstrated enhanced sensitivity for the detection of liver injury as 
compared to ALT.
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Serum K18 and ccK18 have also shown promise as prognostic biomarkers for prediction of 
liver failure and death.28, 29 In these investigations, both K18 and ccK18 levels were 
significantly elevated in patients who met King’s College Criteria (KCC), a model for 
predicting liver failure in AILI, compared to those that did not meet these criteria. 
Estimation of the AI revealed that patients meeting KCC had a lower values (more necrosis) 
compared to those that did not meet KCC. These results are consistent with the idea that 
necrotic liver injury, as opposed to apoptotic injury, is more severe and dangerous.26
It should be noted, however, that calculating an AI can be challenging when utilizing the 
commercially available ELISAs. Experimental evidence conducted in serum from patients 
with cancer suggests that this ratio may not be useful when K18 and ccK18 levels are low, 
near background levels. It is therefore recommended that an AI should be conducted only 
when values of both K18 and ccK18 exceed certain background thresholds.30 Additionally, 
two versions of the ELISA that quantifies total K18, M65® and M65 EpiDeath® are 
available. The newer M65 EpiDeath® kit has been optimized to reduce background antibody 
binding; however, the corresponding ccK18 assay, M30 Apoptosense® ELISA, has currently 
not undergone a similar optimization. Therefore when K18 levels are low, measured ccK18 
levels may exceed measured total K18 levels (unpublished observations) due to increased 
levels of non-specific background binding. Again, this supports the view that an AI should 
be calculated only when values are elevated over a specific background level and when K18 
levels exceed ccK18 levels. The ELISA manufacturer’s now recommend utilizing the older 
version of the K18 ELISA (M65®) when calculation of an AI is desired.31 Finally, these 
ELISAs are not currently available for rodents, making translational studies challenging.
GLDH—GLDH, an enzyme located in the mitochondrial matrix, is involved in amino acid 
oxidation and urea production.32 This protein is primarily expressed in the pericentral region 
of the liver although low levels of GLDH are also observed in the kidney and brain.33 In a 
recent AILI study conducted in rodents, GLDH slightly outperformed ALT for identification 
of hepatocellular necrosis and demonstrated improved correlation with injury severity.34 
Similarly, in a canine study, serum GLDH levels, when compared to ALT levels, were found 
to more accurately reflect the absence of injury histologically observed liver injury at study 
termination.35 A clinical study demonstrated a strong correlation between serum GLDH and 
ALT levels and showed that GLDH displayed high diagnostic power for predicting hepatic 
injury in a large cohort of patients with liver damage resulting from various etiologies.36 It is 
suggested that because the half-life of GLDH is shorter than that of ALT (~16h vs. ~47h, 
respectively), serum levels of GLDH more accurately reflect ongoing liver injury. In muscle 
diseases, such as Muscular Dystrophy serum ALT and AST can exceed 10X ULN.21 
Creatine-kinase, a muscle specific enzyme, can be quantified to determine whether the 
origins of altered ALT are related to muscle injury.37 A problem arises however, when 
patients with underlying muscular disorders are suspected to have liver injury. Unlike ALT, 
serum GLDH is typically within normal limits in patients with Duchenne’s Muscular 
Dystrophy and may therefore be valuable in allowing clinicians to estimate the extent of 
liver damage occurring in this patient population.38 Recently, the Predictive Safety Testing 
Consortium (PSTC) formally proposed to the FDA biomarker qualification program that 
GLDH be considered a DILI biomarker in patients with muscle disease.39 When this 
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manuscript was submitted for publication, the status was listed as “Consultation and 
Advice.”
It has also been proposed that GLDH release into serum may signal mitochondrial toxicity 
as a mechanism underlying the liver injury. This view derives from the fact that if necrosis 
occurs that does not lead to mitochondrial toxicity, intact mitochondria that are released can 
be removed from fresh serum by centrifugation (the “post-mitochondrial supernatant”). 
Using this technique the evidence that GLDH functions as a mitochondrial injury biomarker 
appears supported by research in mice examining GLDH content in post-mitochondrial 
supernatant obtained from AILI or furosemide-induced liver toxicity.40 Although both 
toxicants cause a similar pattern of pericentral necrosis and peak serum ALT elevations, 
significantly elevated levels of GLDH were observed only in post-mitochondrial serum 
supernatant from AILI but not furosemide-treated mice. This is consistent with the known 
mitochondrial toxicity of acetaminophen and the lack of mitochondrial toxicity due to 
furosemide, and suggests that analyzing GLDH in serum post-mitochondrial supernatant 
may provide mechanistic insight during DILI due to many different drugs.
miR-122—MicroRNAs are small, non-coding RNAs that contribute to post-transcriptional 
gene regulation. One attractive feature of these species is their high stability in biofluids. 
MicroRNA-122 is specifically expressed by hepatocytes where it accounts for 70% of the 
total miRNA content found in the liver, making it potentially an ideal candidate as a DILI 
biomarker, given that traditional biomarkers such as ALT are not entirely liver-specific.41
In mice with AILI, miR-122 was found at very high levels in the plasma while being 
concurrently reduced in liver tissue.42 Further, when compared to ALT, circulatory miR-122 
levels became elevated both earlier and following lower doses of APAP. In the clinic, 
multiple DILI studies have demonstrated that circulatory miR-122 levels become elevated 
prior to ALT elevations.25, 27, 43 In another study, serum miR-122 levels were elevated in 
patients with acute liver injury, regardless of etiology, but not in healthy controls or patients 
who took overdoses of acetaminophen but did not develop liver injury.44 Further, miR-122 
levels in samples collected at presentation in AILI patients were enhanced in those who 
experienced a poor outcome (death or liver transplant) compared to those who 
spontaneously recovered. In both this clinical study and in a preclinical study utilizing dogs 
with DILI unrelated to acetaminophen, miR-122 appeared to return to baseline faster than 
ALT, suggesting miR-122 has a shorter serum half-life than ALT and could therefore more 
accurately reflect the extent of ongoing liver injury.35, 44
Large miRNA profiling studies have also been conducted in clinical AILI datasets obtained 
from both adults and children.45–48 In all studies, miR-122 was among the highest elevated 
miRNAs in circulation. Interestingly, in one study that involved evaluation of both AILI and 
ischemic hepatic injury, there was a distinct difference in the profiles of miRNAs between 
the two injury types.45 In the future, miRNA profiling may provide interesting insights into 
mechanistic differences between DILI compounds.
Although there has been much enthusiasm for miR-122 as a sensitive and specific biomarker 
for liver injury, several recent observations have suggested that hepatocyte release of 
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miR-122 may be regulated and may not merely reflect passive release during hepatocyte 
death. For instance, a recent study conducted in rats demonstrated that 2h following 
administration of acetaminophen, treated rats had significantly reduced plasma levels of 
miR-122, compared to control rats.49 Elevated serum levels of miR-122 were observed later, 
coincident with the onset of hepatic necrosis. In addition, it has recently been reported that 
miR-122 is released during an acute phase liver response and may travel to the kidney as a 
cause of anemia often observed in chronic inflammatory conditions.50 miR-122 has also 
been found to have a significantly large degree of both inter- and intra-variability in healthy 
volunteers (manuscript in preparation). This variability, in part, has prompted the PSTC to 
deprioritize miR-122 as a DILI biomarker in favor of GLDH which has lower inter and intra 
subject variability (personal communications).
Biomarkers to predict idiosyncratic DILI
It now appears that many and perhaps most iDILI reactions result from an adaptive immune 
attack on the liver (Figure 2). This requires the body’s immune system to view the liver as 
foreign, presumably as a result of drug-induced creation of novel antigens presented by 
Class I HLA molecules on the surface of liver cells. However, presentation of new antigens 
alone is not thought to be sufficient to elicit an adaptive immune attack on the liver. This is 
believed to require activation of innate immune cells, particularly Kupffer cells within the 
liver. This calls for drug-induced release of damage associated molecular patterns, or 
DAMPs, that initiate activation of the innate immune cells.51 If this is the case, elevations in 
serum ALT in the absence of release of DAMPs, and/or the absence of activation of innate 
immune cells should mean that an adaptive immune attack on the liver will not occur. There 
has therefore been an intense search for the appropriate DAMPs released from liver cells, 
and for biomarkers that can detect activation of innate immune cells in the liver. To date, 
high mobility group box 1 (HMGB1) and its various post-translationally modified forms 
have received most attention in this regard.
HMGB1
This ubiquitous nuclear protein functions primarily in DNA-binding and transcription 
regulation; however it can also be actively secreted into the extracellular milieu.52 Evidence 
suggests that HMGB1 is released passively into circulation from injured or dying liver cells 
and can act as a DAMP, initiating an immune response.53 This function appears to be 
mediated by the redox state of specific residues within HMGB1. HMGB1 isoforms that are 
fully or partially reduced at these residues are characteristically released during necrosis and 
facilitate chemotaxis and cytokine release from innate immune cells. Conversely, HMGB1 
that is fully oxidized at these key sites is characteristically released by apoptotic cells and 
does not elicit an innate immune response.54
It may be important that HMGB1 can also be actively secreted in a process that requires 
hyper-acetylation of critical lysine residues. When detected in serum during a DILI event, 
most hyper-acetylated HMGB1 is believed to have been released by innate immune cells, 
signifying activation by DAMPs; however, hepatocytes have also been shown to secrete this 
isoform under certain conditions (Figure 1).55, 56
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Both non-clinical and clinical studies have demonstrated HMGB1 to be a sensitive 
biomarker of AILI. In mice, total serum HMGB1 became significantly increased earlier than 
ALT and returned to baseline more rapidly, correlating well with serial histopathological 
assessments of liver necrosis.24 Consistent with the idea that leakage of HMGB1 from 
necrotic cells stimulates inflammation and active release of HMGB1 from immune cells, 
elevation of hyper-acetylated HMGB1 in serum occurred concurrently with the appearance 
of inflammatory cells in the liver. Moreover, treatment with a chimeric humanized anti-
HMGB1 antibody reduced liver injury due to acetaminophen in a recent mouse study, 
supporting a role of this protein in the progression of DILI due to this drug.57
In clinical AILI studies, HMGB1 displayed enhanced sensitivity for hepatotoxicity 
detection, compared to ALT.25, 26, 43 In one study, measurements were collected at 
presentation from patients whose ALT levels were still within the normal range. In these 
samples, total HMGB1 levels were significantly increased only in patients who later 
developed hepatic injury.25 In a second study, hyper-acetylated HMGB1 was observed only 
in AILI patients who died or needed a liver transplant, compared to those who 
spontaneously survived, suggesting that this form of HMGB1 may be prognostic for a poor 
outcome in AILI.26
While total HMGB1 can be quantified by immunoassay, there are currently no antibodies 
that can decipher different isoforms, necessitating mass spectrometry to determine the post-
translational states of HMGB1. Nevertheless, the measurement of total HMGB1 was also 
demonstrated to be a sensitive biomarker for DILI in the above described AILI studies.
Exosomes
As discussed above, DAMPs are released during hepatocyte necrosis and initiate activation 
of innate immune cells in the liver which is proposed to be necessary but not sufficient to 
initiate an adaptive immune attack on the liver. However, there is growing evidence that 
hepatocyte necrosis is not necessarily a prerequisite for the release of DAMPs and ultimate 
initiation of an adaptive immune attack on the liver. For example, strong HLA associations 
have been observed with relatively minor elevations in serum ALT in clinical trials of 
ximelagatran, lumiracoxib and lapatinib.58–60 In addition, in the case of iDILI due the 
antibiotic isoniazid, drug reactive T-cells have been identified in patients’ blood prior to the 
onset of elevations in serum ALT.61 These observations suggest that mild elevations in 
serum ALT do not necessarily reflect direct drug-induced hepatocyte necrosis that could 
then initiate an adaptive immune attack, but rather that the initial hepatocyte death is 
mediated by an adaptive immune attack. That an adaptive immune attack on the liver can be 
triggered in the absence of hepatocyte death is consistent with hepatitis B infection. The 
hepatitis B virus is not cytolytic yet generates a liver-specific adaptive immune attack 
resulting in hepatocyte necrosis and the clinical disease.62 Recent data suggest that the 
DAMPs may travel in hepatocyte-derived exosomes and be released by drug-induced 
hepatocyte stress in the absence of cell death.49 Unpublished observations also suggest that 
exosomes released from hepatocytes treated with sub- toxic doses of acetaminophen produce 
greater activation of monocytes than exosomes released from control hepatocytes 
(manuscript in preparation). It is plausible that stressed but not dying hepatocytes release 
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DAMPs (and possibly the neoantigens) in exosomes which then travel to and activate innate 
immune cells. This is an important area of investigation because, due to the porous 
fenestrations in liver endothelia, liver-derived exosomes can enter circulation and potentially 
serve as blood biomarkers. It may therefore be that isolation of exosomes from peripheral 
blood, and profiling them for DAMPs such as HMGB1, may provide the earliest biomarker 
predictive of progressive and clinically important DILI potential.
The future
Although they are unlikely to replace traditional biomarkers in general practice, the addition 
of new candidate biomarkers to standard measurements could soon transform DILI 
prediction, detection, and risk management. For instance, data has demonstrated that 
quantification of candidate biomarkers would have enabled early administration of n-acetyl 
cysteine to a patient who developed significant AILI following a self-reported drug over 
dose.43 While this patient had no ALT elevation at presentation (4.5 hours post-over dose) 
and was sent home without treatment, he eventually developed significant liver injury. 
Retrospective analysis revealed substantial elevation of K18, HMGB1, and miR-122 in the 
blood sample collected at presentation.
Further, some of these biomarkers are already being used in early clinical trials with the 
hope of distinguishing benign elevations in serum ALT from those that portend potential for 
progressive liver injury, perhaps even to predict potential for very rare iDILI events. Take for 
example elevations in serum ALT/AST and bilirubin attributed to a new drug candidate in a 
clinical trial. The bilirubin elevations might be completely accounted for by the quantitative 
systems pharmacology modeling based on the drugs ability, determined in in vitro 
experimental systems, to inhibit bilirubin transporters and/or UGT 1A1, together with 
estimates of the serum ALT based estimated of percent hepatocyte described above. The 
serum ALT elevations might further be viewed as benign “transaminitis,” even if the GLDH/
miR-122 assessments indicate hepatic origin, if a) the serum AI suggested hepatocyte death 
is primarily due to apoptosis, b) only inactive DAMPs are detected concomitantly in serum 
and c) serum biomarkers of innate immune activation are not detected. The modified forms 
of HMGB1 may be helpful here, but more work is necessary to define their roles, as hyper-
acetylated HMGB1 was detected in healthy volunteers during serum ALT elevations due to 
heparins, which are entirely safe for the liver.63
One major challenge is that most of our current knowledge regarding investigational 
biomarkers of DILI has been gained from relatively few patient populations, primarily those 
experiencing AILI. In order to establish both the context of use and the limitations for each 
of these candidate biomarkers, it is necessary to study their performance in many different 
patient populations, especially patients experiencing DILI unrelated to AILI. In 
collaboration with the Safer Faster Evidence-based Translation (SAFE-T) and PSTC, the 
Drug-Induced Liver Injury Network (DILIN) is exploring a number of candidate DILI 
biomarkers, including several that were included in this review (manuscript in 
preparation).64–66 However, the majority of serum specimens available to investigators are 
from patients once they are already found to be experiencing DILI and it is therefore not 
possible to assess the ability of the biomarkers to predict DILI before it occurs. The ability 
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to predict DILI before it occurs would best be assessed in serum samples prospectively 
collected and archived during clinical trials. Unfortunately, serial serum samples collected 
during trials for the purpose of monitoring and evaluating perceived alterations in safety 
signals are not routinely collected, and companies are often not eager to subject what 
samples have been archived to exploratory studies. Perhaps a “safe haven” needs to be 
created by regulatory agencies to house such data, as exemplified by the FDA’s Guidance on 
Voluntary Genomic Data Submissions.67
An additional caveat is that current candidate biomarkers are not specific to DILI, i.e. 
hepatic injury of various etiologies results in increased serum levels of these markers. For 
instance, elevated levels of K18 and ccK18 are reported with hepatitis, fibrosis, and non-
alcoholic fatty liver disease.68 GLDH, HMGB1, and miR-122 elevations are also associated 
with liver injuries unrelated to DILI.36, 69, 70 As noted earlier, microRNA profiling identified 
distinct miRNA changes between AILI and ischemic liver injury.45 “Omics” type 
approaches, in which large numbers of molecules are measured concurrently, such as 
microRNA profiling, metabolomics, or proteomics, may in the future be useful for 
identifying unique DILI signatures and/or for identifying novel candidate biomarkers with 
improved performance for DILI detection. Omics technologies for biomarker discovery, 
however, have been described elsewhere and are outside the scope of the current review.
In conclusion, while preliminary data surrounding the performance of candidate biomarkers 
in DILI is very promising and is likely to transform DILI assessment and management in the 
future, further work is necessary before there is universal acceptance of these biomarkers. In 
reality, it is unlikely that a single candidate biomarker will emerge as the new “gold 
standard.” It is more likely that a panel of candidate biomarkers, perhaps in partnership with 
both traditional biomarkers and quantitative systems pharmacology modeling approaches 
may give the most complete picture of DILI risk and guide improved risk management 
strategies.
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Key Points
• Traditional DILI biomarkers are not liver-specific, mechanistically 
informative, or sufficiently predictive of a serious DILI liability.
• Quantitative systems pharmacology can aid in the interpretation of traditional 
liver chemistry elevations.
• An “apoptotic index” may inform on DAMP leakage, innate immune 
activation, and severity of DILI.
• miR-122 and GLDH are more liver-specific than ALT and may become 
important measurements when the origin of ALT release is unclear.
• Quantification of DAMPs, released passively during necrosis or actively as 
exosomal cargo, and biomarkers of innate immune activation together with 
systems pharmacology modeling show promise early prediction of serious 
DILI events.
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Figure 1. The origin of candidate biomarkers for DILI
MicroRNA-122 and GLDH are candidate biomarkers that appear to be specific to the liver 
(red stars). Necrotic cell death results in the release of HMGB1 that is fully or partially 
reduced at key cysteine residues and therefore acts as a “Damage Associated Molecular 
Pattern,” or DAMP. Necrotic hepatocytes also release full length K18 (FL-K18), and GLDH. 
In contrast, hepatocytes undergoing apoptotic cell death release HMGB1 fully oxidized at 
key cysteine residues, which is not a DAMP, and caspase cleaved K18 (ccK18). The 
“apoptotic index” is the ratio of ccK18/K18 and is proposed to estimate the relative 
proportion of apoptosis vs, necrosis occurring during a DILI event. DAMPs activate innate 
immune cells such as Kupffer cells which then release hyperacetylated HMGB1.
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Figure 2. Proposed sequence of events in idiosyncratic DILI involving adaptive immunity
In order to initiate an adaptive immune attack on the liver, it is proposed that drug must 
cause hepatocyte stress or death leading to release of Damage Associated Molecular Patterns 
(DAMPs) which in turn activate innate immune cells, particularly Kupffer cells in the liver. 
The activated innate immune cells release cytokines and chemokines that draw inflammatory 
cells into the liver, a process thought to be a prerequisite for a targeted adaptive immune 
attack on the liver. The biomarkers in Figure 1 may be useful in detecting the initial steps 
and thereby identify potential for severe DILI events before they occur.
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